Zavesca has been proven to reduce liver and spleen enlargement in people with type 1 Gaucher disease. As you can see by looking at the charts below, reductions in liver and spleen size continued over time in people taking Zavesca.1-3 Zavesca has also been shown to increase the amount of hemoglobin (hemoglobin concentration) and the number of platelets (platelet count) in people with type 1 Gaucher disease.1-3

In one clinical trial, the benefits of long-term ERT were maintained in people who switched to Zavesca. People with type 1 Gaucher disease who had been taking ERT for an average of 5.6 years maintained the benefits of ERT in liver and spleen size, hemoglobin concentration, and platelet count after 6 months on Zavesca.2,3

1. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s
disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate
biosynthesis. Lancet. 2000;355:1481–1485.
2. Zavesca® (miglustat) package insert. Actelion, Ltd. 2003.
3. Data on file, Actelion Pharmaceuticals US, Inc.